DR CARRION FULL

This highlighted to me the complexity and reward of the relationships we have with our patients, and the impact these relationships can have in their well-being.Īn increasing prevalence of early childhood adversity has reached epidemic proportions, creating a public health crisis. As healthcare providers, many of us represented the only relationships these patients had. The AIDS virus rendered vulnerable many young people who were already defenseless and without social, financial and emotional support.

DR CARRION FULL

I am proud to work with colleagues of various disciplines and approaches we all share the same goal of helping each child live a better life and develop to their full potential.ĭuring the early 80s, while in medical school, I witnessed many young people struggle alone with a disease that few understood and at the time was considered a death sentence. This is the meaning of personalized care. Listening empathically matched with comprehensive data-gathering helps us avoid reacting too quickly or impulsively, out of preconceived ideas. I work toward understanding the struggles of children and families and this informs my clinical approach. To advance our development of therapeutic antibodies for treatment of Ebolavirus disease, we have recently teamed with BARDA, the Biomedical Advanced Research and Development Authority.Excellent care starts with listening. This technology uses on-chip fluorescence detection for biosensing applications. In our efforts to discover new detection methods for bioterror agents, we recently teamed up with a local biotechnology company to test an Handheld Aptamer-Magnetic Bead-Quantum Dot Sensor for Crimean Congo Hemorrhagic Fever (CCHF), a tick- borne disease causing hemorrhagic fever in eastern Europe, Asia, India and Africa, with hospitalized patient fatality rates ranging from 9 to 50 percent.Īdditionally, we collaborated with researchers to develop an optofluidic analysis system for amplification-free, direct detection of Ebola infection.

This indicates that c-Abl regulates budding or release of filoviruses, offering a potential new target for antiviral therapy. Replication of the highly pathogenic Ebola virus strain Zaire, responsible for the recent (2014-15) Ebola virus epidemic in West Africa, was inhibited by c-Abl1-specific siRNAs or by the Abl-family inhibitor nilotinib.

Our lab has shown that two drugs available for leukemia treatment can also block Ebola replication in vitro. Several vaccine candidates that were previously tested with success at Texas Biomed are now part of human clinical safety trials. Most have shown efficacy in smaller animal models and will be validated in nonhuman primate models of disease at Texas Biomed. Most recently, we have been awarded contracts to test the efficacy of several vaccine platforms against filoviruses, including multivalent virus like particle (VLP) vaccines, adeno-vectored vaccines, and modified vaccinia ankara (MVA) vaccines. Identification of this rodent-sized nonhuman primate model is so important because marmosets are more predictive of therapeutic efficacy than traditional small animal models. We have shown that marmosets, small new world monkeys weighing less than 400 grams, exhibit disease effects similarly to humans, and can serve as a small nonhuman primate model for filovirus-induced hemorrhagic fever.

In support of filovirus vaccine development, we have developed the common marmoset as a nonhuman primate model for Ebola and Marburg virus disease. These viruses have also been responsible for an 88 percent decline in the world’s chimpanzee populations since 2003. Filoviruses, such as Ebola virus and Marburg virus, are examples of highly lethal agents that induce hemorrhagic fever with a mortality rate of up to 90 percent.

Dr carrion